Atrasentan not checked

Novartis · CHK01 · EXV811

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
4 active
5 in total · 3 in the EU
Targets
—
None known yet

What this is

How it works
Blocks endothelin, a signal that tightly narrows blood vessels.Endothelin Receptor Antagonist FDA class
How it’s given
“* 104 Weeks - Film-coated tablet * Other Names: Atrasentan Hydrochloride ABT-627”In the company’s words, NCT07498335 on ClinicalTrials.gov
Tested for
IgA Nephropathy (3 trials), Immunoglobulin A Nephropathy (3 trials), IgA Nephropathy (IgAN), Berger Disease, Bergers Disease, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type, Focal Segmental Glomerulosclerosis and 3 more
Main trialPhase 3
“The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.”In the company’s words, NCT04573478 on ClinicalTrials.gov
Other names
CHK01 · EXV811 · CHK-01 · ABT-627

Other drugs for IgA Nephropathy

All 39 drugs for IgA Nephropathy

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 14 Apr 2028 Atrasentan in Patients With IgA Nephropathy
Phase 3Not yet recruiting 17 Sep 2028 A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
Phase 3Recruiting 15 Sep 2031 Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Phase 2Active, not recruiting 2 Jul 2024 Atrasentan in Patients With Proteinuric Glomerular Diseases
Phase 2Completed 30 Jun 2025 Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Atrasentan

Following is part of Solo: you see every change to Atrasentan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in